• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Context Clinical practice guidelines on the management of mineral and bone disorders due
to chronic kidney disease recommend specific treatment target levels for serum phosphorus …

Hyperphosphatemia, which is nearly universal in kidney failure, is accompanied by low
serum levels of vitamin D and hypocalcemia. Without treatment, severe secondary …

This commentary provides a US perspective on the 2009 KDIGO (Kidney Disease:
Improving Global Outcomes) Clinical Practice Guideline for the Diagnosis, Evaluation …

Interventions To Attenuate Vascular Calcification Progressio... : Journal of the American
Society of Nephrology Interventions To Attenuate Vascular Calcification Progression in Chronic …

Arterial calcification, common in vascular diseases, involves vascular smooth muscle cell
(VSMC) transformation to an osteoblast phenotype. Clinical studies suggest that magnesium …

CKD mineral and bone disease is a common complication of kidney disease, and it affects
the majority of patients with moderate to severe CKD. Recently, prospective studies have …

Background Serum phosphate is a known risk factor for cardiovascular events and mortality
in people with chronic kidney disease (CKD), however data on the association of these …

Results We found 26 systematic reviews, RCTs, or observational studies that met our
inclusion criteria. We performed a GRADE evaluation of the quality of evidence for …

Phosphate binders include calcium acetate or carbonate, sevelamer hydrochloride or
carbonate, magnesium and lanthanum carbonate, and aluminum carbonate or hydroxide …